Company / Accounts Receivable
Abbott Laboratories Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$7.9B
FY2025
5-year range
$6.2B / $7.9B
FY2021-FY2025
Trend
+14.5%
vs FY2024
Sector context
#6 of 138
Health Care
What the data says
Among 138 Health Care companies, Abbott Laboratories is in the top 4% for accounts receivable. Accounts Receivable has increased for 3 consecutive years, from $6.2B in FY2022 to $7.9B in FY2025.
Based on SEC 10-K filings.
$7.9B in FY2025 with a 5-year CAGR of +4.3%. Top quartile in the Health Care sector.
Improved from $6.6B to $7.9B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +8.4%
- 5-Year CAGR
- +4.3%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 138This company $7.9B Sector average $1.3B
▼
+500.4% above sector average
Key checks
Key Insights
- Abbott Laboratories's accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of +4.3%, indicating consistent growth.
- In FY2025, accounts receivable increased 14.5% year-over-year.
- Ranks #6 out of 138 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.9B | +14.5% |
| FY2024 | $6.9B | +5.5% |
| FY2023 | $6.6B | +5.6% |
| FY2022 | $6.2B | -4.1% |
| FY2021 | $6.5B | +1.1% |
| FY2020 | $6.4B | +18.2% |
| FY2019 | $5.4B | +4.7% |
| FY2018 | $5.2B | -1.3% |
| FY2017 | $5.2B | +61.6% |
| FY2016 | $3.2B | -5.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026